Patent US4264582A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4264582A Expired / Lapsed US ⏱️ 0.0 years remaining

Isobutylphenylacetate anti-inflammatory composition

Assignee: Procter and Gamble Co
•
Filing: 1979-10-22
•
Granted: 1981-04-28
•
Expires: 1999-10-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The anti-inflammatory activity of ibuprofen, ibufenac and other p-(isobutylphenyl)acetic acid-based anti-inflammatory drugs is enhanced by adminstration thereof in conjuction with a phosphonate compound such as EHDP or Cl2MDP.

Inventors

  • 👤 Lawrence Flora
  • 👤 Marion D. Francis

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-27 07:08
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 178 words
A method for treating or preventing pain and inflammation in animal tissues, comprising administering to an animal in need of such treatment from about 50 mg to about 6000 mg per day of a p-(isobutylphenyl)acetic acid-based anti-inflammatory compound selected from the group consisting of ibufenac, ibuprofen, and pharmaceutically-acceptable salts and esters thereof, and from about 200 mg to about 2,000 mg per day of an organophosphonate compound selected from the group consisting of geminal organophosphonates of the formula ##STR5## or pharmaceutically-acceptable salts thereof, wherein n is an integer from 1 to about 10; R 3 is selected from the group consisting of H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is selected from the group consisting of H, lower alkyl, amino, benzyl, halogen, --OH, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 .
Claim 2
Independent Claim 178 words
A method for treating or preventing pain and inflammation in animal tissues, comprising administering to an animal in need of such treatment from about 50 mg to about 6000 mg per day of a p-(isobutylphenyl)acetic acid-based anti-inflammatory compound selected from the group consisting of ibufenac, ibuprofen, and pharmaceutically-acceptable salts and esters thereof, and from about 200 mg to about 2,000 mg per day of an organophosphonate compound selected from the group consisting of geminal organophosphonates of the formula ##STR5## or pharmaceutically-acceptable salts thereof, wherein n is an integer from 1 to about 10; R 3 is selected from the group consisting of H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is selected from the group consisting of H, lower alkyl, amino, benzyl, halogen, --OH, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 .
Claim 3
Dependent Claim 19 words
A method according to claim 1 wherein the organophosphonate compound is a geminal organophosphonate having n equal to 1.
Claim 4
Dependent Claim 32 words
A method according to claim 2 wherein the organophosphonate compound is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid, dichloromethanediphosphonic acid, methanediphosphonic acid, and the pharmaceutically-acceptable salts and esters thereof.
Claim 5
Dependent Claim 12 words
A method according to claim 1 wherein the animal is a human.
Claim 6
Dependent Claim 33 words
A method according to claim 4 which employs a safe and effective amount of ibufenac or ibuprofen and a safe and effective amount of dichloromethanediphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.
Claim 7
Dependent Claim 33 words
A method according to claim 4 which employs a safe and effective amount of ibufenac or ibuprofen and a safe and effective amount of ethane-1-hydroxy-1,1-diphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.
Claim 8
Dependent Claim 33 words
A method according to claim 4 which employs a safe and effective amount of ibufenac or ibuprofen and a safe and effective amount of methanediphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.
Claim 9
Independent Claim 23 words
A method according to claims 1 or 3 wherein the p-(isobutylphenyl) acetic acid-based compound is ibuprofen or a pharmaceutically-acceptable salt or ester thereof.
Claim 10
Dependent Claim 164 words
A composition of matter for treating pain and inflammation in animal tissue, comprising from about 10 mg to about 500 mg of a p-(isobutylphenyl) acetic acid-based compound selected from the group consisting of ibufenac, ibuprofen and pharmaceutically-acceptable salts and esters thereof, and from about 50 mg to about 250 mg of an organophosphonate compound selected from the group consisting of geminal organophosphonates of the formula ##STR6## or pharmaceutically-acceptable salts thereof, wherein n is an integer from 1 to about 10; R 3 is selected from the group consisting of H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH(PO 3 H 2 )(OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is selected from the group consisting of H, lower alkyl, amino, benzyl, halogen, --OH, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 .
Claim 11
Dependent Claim 164 words
A composition of matter for treating pain and inflammation in animal tissue, comprising from about 10 mg to about 500 mg of a p-(isobutylphenyl) acetic acid-based compound selected from the group consisting of ibufenac, ibuprofen and pharmaceutically-acceptable salts and esters thereof, and from about 50 mg to about 250 mg of an organophosphonate compound selected from the group consisting of geminal organophosphonates of the formula ##STR6## or pharmaceutically-acceptable salts thereof, wherein n is an integer from 1 to about 10; R 3 is selected from the group consisting of H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH(PO 3 H 2 )(OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is selected from the group consisting of H, lower alkyl, amino, benzyl, halogen, --OH, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 .
Claim 12
Dependent Claim 19 words
A composition according to claim 9 wherein the organophosphonate compound is a geminal organophosphonate having n equal to 1.
Claim 13
Dependent Claim 32 words
A composition according to claim 10 wherein the organophosphonate compound is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid, dichloromethanediphosphonic acid, methanediphosphonic acid, and the pharmaceutically-acceptable salts and esters thereof.
Claim 14
Dependent Claim 40 words
A composition according to claim 9, comprising a safe and effective amount of a member selected from the group consisting of ibufenac and ibuprofen, and a safe and effective amount of dichloromethanediphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.
Claim 15
Dependent Claim 23 words
A composition according to claims 9 or 11 wherein the p-(isobutylphenyl) acetic acid-based compound is ibuprofen or a pharmaceutically-acceptable salt or ester thereof.
Claim 16
Dependent Claim 38 words
A composition according to claim 9, comprising a safe and effective amount of a member selected from the group consisting of ibufenac and ibuprofen, and a safe and effective amount of ethane-1-hydroxy-1,1-diphosphonic acid, or the pharmaceutically-acceptable salts thereof.
Claim 17
Dependent Claim 40 words
A composition according to claim 9 comprising a safe and effective amount of a member selected from the group consisting of ibufenac and ibuprofen, and a safe and effective amount of methanediphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.

References Cited (Backward Citations)

US3553314A Cited
US3584125A Cited
US3553315A Cited
US3584124A Cited
US3678164A Cited
US3641246A Cited
US3662066A Cited
US3683080A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-04-27 1984-10-27 1985-04-28 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-04-27 1988-10-27 1989-04-28 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-04-27 1992-10-27 1993-04-28 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag